ライフサイエンスコーパス: 5-HT1A receptor

1 elective, with subnanomolar affinity for the 5-HT1A receptor.

2 ignificantly greater affinity than 1a at the 5-HT1A receptor.

3 leus in compounds that bind to the serotonin 5-HT1A receptor.

4 AHP resulted from altered expression of the 5-HT1A receptor.

5 eled oligonucleotide probes specific for the 5-HT1A receptor.

6 hamster ovary cell line expressing the human 5-HT1A receptor.

7 onin may represent a deficiency of serotonin 5-HT1A receptor.

8 ike effect of D1 and possible involvement of 5-HT1A receptor.

9 intrinsic activity (E max = 26 +/- 2.0%) on 5-HT1A receptor.

10 ceptor in recombinant cells expressing human 5-HT1A receptor.

11 at serotonin is primarily acting through the 5-HT1A receptor.

12 nist-dependent endocytosis of epitope-tagged 5-HT1A receptors.

13 via 5-HT2A receptors and hyperpolarised via 5-HT1A receptors.

14 controlled by 5-HT stimulation of astrocytic 5-HT1a receptors.

15 and D3 dopamine (DA) receptors and serotonin 5-HT1A receptors.

16 polarization mediated by serotonin acting on 5-HT1A receptors.

17 ne ([125I]p-MPPI), a selective antagonist of 5-HT1A receptors.

18 3H]8-OH-DPAT from rat hippocampal homogenate 5-HT1A receptors.

19 in substantia nigra and in areas containing 5-HT1A receptors.

20 dopamine D2, serotonin 5-HT2, and serotonin 5-HT1a receptors.

21 te less than 50-fold selectivity relative to 5-HT1A receptors.

22 ed with the known postmortem distribution of 5-HT1A receptors.

23 isplays little selectivity for 5-HT1D versus 5-HT1A receptors.

24 ceptors and as an antagonist at postsynaptic 5-HT1A receptors.

25 H]-8-OH-DPAT from rat hippocampal homogenate 5-HT1A receptors.

26 ylpiperazine ([(18)F]MPPF), an antagonist of 5-HT1A receptors.

27 A, gamma-aminobutyric acid (GABA)B , BZ, and 5-HT1A receptors.

28 HT to a concentration sufficient to activate 5-HT1A receptors.

29 hypothalamus and hippocampus is mediated by 5-HT1A receptors.

30 rotonin transporter (SERT) and serotonin 1A (5-HT1A) receptor.

31 , pretreatment with a specific antagonist of 5-HT1A receptors, 4-iodo-N-[2-[4-(methoxyphenyl)-1-piper

32 ne ring present in the previously identified 5-HT1A receptor (5-HT1AR) ligand 3.

33 beta have the highest homology to the human 5-HT1A receptor (71.5% and 63.7%, respectively).

34 the lipid dependence of the human serotonin 5-HT1A receptor, a GPCR that is central to neuronal func

35 e which members of the Gi/o/z family mediate 5-HT1A receptor-activated Na+/H+ exchange as measured by

36 betagamma-subunits, a maneuver that blocked 5-HT1A receptor activation of mitogen-activated protein

37 f so, whether the increase is dependent upon 5-HT1A receptor activation.

38 n syndrome" and salivation, an indication of 5-HT1A receptor activation.

39 suppress the antidepressant-like effects of 5-HT1A receptor activation.

40 ncourage future studies of the mechanisms of 5-HT1A receptor activity in brain and the action of drug

41 resistance to the hypothermic effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)te

42 Treatment with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylmino)tet

43 tested for behavior under effective doses of 5-HT1A receptor agonist 8-hydroxy-N, N-dipropyl-2-aminot

44 When superfused before tetanus, the 5-HT1A receptor agonist 8-hydroxydipropylamino-tetralin

45 cerebrospinal fluid (aCSF) or the selective 5-HT1A receptor agonist 8-OH-DPAT (50-200 ng) and tested

46 (LDS) hypothermic responses to the specific 5-HT1A receptor agonist 8-OH-DPAT.

47 OH-DPAT; 200 ng), or were coinfused with the 5-HT1A receptor agonist and the 5-HT3 receptor agonist,

48 The lordosis-inhibiting effects of the 5-HT1A receptor agonist, (+/-)8-hydroxy-2-(di-n-propylam

49 ts received bilateral VMN infusions with the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)

50 intraperitoneal injections of saline or the 5-HT1A receptor agonist, 8-OH-DPAT (1 mg/kg), for 7 days

51 The effects of the selective serotonin 5-HT1A receptor agonist, 8-OH-DPAT (20 microM) on GEPR-9

52 ted following systemic administration of the 5-HT1A receptor agonist, 8-OH-DPAT, the D2 receptor anta

53 Treatment with another 5-HT1A receptor agonist, buspirone (1.5 mg/kg, i.p.), re

54 Identical results were obtained with another 5-HT1A receptor agonist, buspirone (1.5 mg/kg, i.p.; n =

55 ropylamino)tetralin (8-OH-DPAT), a selective 5-HT1A receptor agonist, in artificial CSF.

56 2-(di-n-propylamino) tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, into the lateral cerebral ventr

57 genic 5-HT2A /2C receptor agonist, but not a 5-HT1A receptor agonist, resulted in a significant but d

58 te brain, in contrast to 8-OH-DPAT, a potent 5-HT1A receptor agonist.

59 Three 5-HT1A receptor agonists (8-OH-DPAT, F13714 and F15599)

60 We conclude that 5-HT1a receptor agonists have two competing effects: rap

61 f dihydrofuroaporphine bind to the serotonin 5-HT1A receptor and exert opposite effects.

62 that this effect of 5-HT was mediated by the 5-HT1A receptor and may be secondary to inhibition of N-

63 Further investigation into the role of the 5-HT1A receptor and the potential of [11C]-WAY100635 PET

64 an agonist at presynaptic (somatodendritic) 5-HT1A receptors and as an antagonist at postsynaptic 5-

65 bited these cells directly via activation of 5-HT1A receptors and indirectly via enhanced GABA releas

66 sibly via central alpha2-adrenoceptor and/or 5-HT1A receptors and not through H2-histamine or I1-imid

67 fferences in the degree of G protein-coupled 5-HT1A receptors and suggest that fluoxetine-induced des

68 ed the distribution of [3H]8-OH-DPAT-labeled 5-HT1A receptors and their degree of coupling to G prote

69 measured in brain is dominated by binding to 5-HT1A receptors and to reveal the extent of defluorinat

70 tance P, imply constitutive activity for the 5-HT1A receptor, and demonstrate for the first time that

71 to identify cells that contain mRNA encoding 5-HT1A receptors, and immunocytochemistry was employed t

72 onto Receptor (Type II) cells by activating 5-HT1A receptors, and reducing ATP secretion.

73 that preferential activation of presynaptic 5-HT1A receptors, and subsequent inhibition of serotonin

74 -HT release throughout the DR, activation of 5-HT1A receptors, and subsequent inhibition.

75 nding of [3H]8-OH-DPAT to both the 5-HT7 and 5-HT1A receptors, and that the latter receptor subtype i

76 profile of 5-HT(1A-1D) and 5-HT2 receptors, 5-HT1A receptors, and the serotonin (5-HT) transporter (

77 ing of pallidal neurons through postsynaptic 5-HT1A receptors; and (3) 5-HT postsynaptically excites

78 nists (8-OH-DPAT, F13714 and F15599) and one 5-HT1A receptor antagonist (MPPF) were compared in terms

79 35) (0.3-10 mg/kg) but was unaffected by the 5-HT1A receptor antagonist 4-iodo-N-[2-[4-(methoxyphenyl

80 Instead, CUMI-101 behaved as a potent 5-HT1A receptor antagonist by dose-dependently inhibitin

81 nduced increase in social behaviors, while a 5-HT1A receptor antagonist did not alter affiliative voc

82 infused with WAY100635 (400 to 2000 ng), the 5-HT1A receptor antagonist did not facilitate lordosis r

83 CUMI-101 behaves as a 5-HT1A receptor antagonist in primate brain, with signif

84 udy showed that CUMI-101 behaved as a potent 5-HT1A receptor antagonist in rat brain.

85 PAT was completely reversed by the selective 5-HT1A receptor antagonist WAY 100,635 (100 micrograms/k

86 ntagonist SB 216641 (10 microM), but not the 5-HT1A receptor antagonist WAY 100635 (10 microM) or the

87 on channels and was blocked by the selective 5-HT1A receptor antagonist WAY-100635 (100 nM).

88 y 8-OH-DPAT persisted in the presence of the 5-HT1A receptor antagonist WAY-100635, was abolished by

89 antagonist), WAY-100635 (selective serotonin 5-HT1A receptor antagonist) as well as monoamine oxidase

90 1D/1A) receptor antagonist) or WAY 100635 (a 5-HT1A receptor antagonist).

91 contribute to propranolol's action since the 5-HT1A receptor antagonist, (S)-WAY 100135 (P = 0.2), an

92 n emission tomography imaging and a specific 5-HT1A receptor antagonist, [carbonyl-11C]WAY-100635.

93 with yohimbine, the alpha2-adrenoceptor and 5-HT1A receptor antagonist, blocked the cardiovascular r

94 rying concentrations (200 to 2000 ng) of the 5-HT1A receptor antagonist, N-[2[4-(2-methoxyphenyl)-1-p

95 came from the finding that (-)-tertatolol, a 5-HT1A receptor antagonist, reversed this effect at a do

96 5-HT2C receptor antagonist, SB242084, or the 5-HT1A receptor antagonist, WAY-100635, and were tested

97 ing serotonin (5-HT) reuptake inhibitors and 5-HT1A receptor antagonists.

98 ypercapnia, but not to hypoxia, and that MRR 5-HT1A receptors are also involved in thermoregulation a

99 ic localization in hippocampal region, where 5-HT1A receptors are concentrated.

100 Although 5-HT1A receptors are involved in controlling the activit

101 These results demonstrate that 5-HT1A receptors are involved in the modulation of explo

102 Presynaptic dorsal raphe neuron (DRN) 5-HT1A receptors are known to have a critical role in af

103 The 5-HT1A receptors are located both presynaptically and po

104 Earlier investigations have suggested that 5-HT1A receptors are synthesized in enteric, but not pan

105 es and its autoregulation by somatodendritic 5-HT1A receptors are well described, but little is known

106 Serotonin 1A (5-HT1A) receptors are involved in several physiological

107 These animals lack functional 5-HT1A receptors as indicated by receptor autoradiograph

108 hippocampus while increasing the efficacy of 5-HT1A receptors as measured by agonist-stimulated [35S]

109 pharmacology showed that focal activation of 5-HT1A receptors at the axon initial segment (AIS), but

110 ectly regulate the expression of hippocampal 5-HT1A receptors at the mRNA level in cultured hippocamp

111 we investigated the relationship between DRN 5-HT1A receptor availability and amygdala reactivity to

112 processing and the relationship between DRN 5-HT1A receptor availability and amygdala reactivity.

113 Alterations in DRN 5-HT1A receptor availability cause phenotypes characteri

114 Our data show that DRN 5-HT1A receptor availability is linked specifically to t

115 However, it is unknown whether 5-HT1A receptor availability is linked specifically to t

116 we tested drugs that stimulate serotonin 1A (5-HT1A) receptors, based on our previous findings that t

117 A significant increase in 5-HT1A receptor binding density was observed across infa

118 ) and [11C--carbonyl] WAY100635, we assessed 5-HT1A receptor binding in 21 healthy subjects (10 men,

119 We observed increased 5-HT1A receptor binding in women who had recovered from

120 exception of the hypoglossal nucleus, where 5-HT1A receptor binding increases while SERT binding rem

121 5-HT1A receptor binding is also associated with treatmen

122 The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalk

123 Regional estimates of 5-HT1A receptor binding potential (nondisplaceable) were

124 gate the relationship of body temperature of 5-HT1A receptor binding sites, autoradiographic analyses

125 Specific 5-HT1A receptor binding was assessed using the binding p

126 However, 5-HT1A receptor binding was associated with a measure of

127 an age, 25.1 +/- 5.8 years).Intervention The 5-HT1A receptor binding was measured using positron emis

128 hey exhibit reduced 5-HT neuron activity and 5-HT1A receptor binding with varying changes in postsyna

129 d by either 5-HT2A/C receptor stimulation or 5-HT1A receptor blockade of naive control pups.

130 n expression of human 5-hydroxytryptamine1A (5-HT1A) receptors by agonists and antagonists was studie

131 s synthesized and tested for affinity at the 5-HT1A receptor, by competition with [3H]-8-OH-DPAT in r

132 f 8-OH-DPAT (50 ng) was due to activation of 5-HT1A receptors came from the finding that (-)-tertatol

133 Our data suggest that expression of 5-HT1A receptors can be regulated by both agonists and a

134 t intracellular mechanisms downstream of the 5-HT1A receptor capable of inhibiting the AHP were intac

135 e of partial agonist activity at both D2 and 5-HT1A receptors causing partially decreased synthesis o

136 was required for a maximal affinity shift of 5-HT1A receptors compared with 5-HT1B receptors (EC50 va

137 A receptor protomer in the hippocampal FGFR1-5-HT1A receptor complex enhancing the FGFR1 signaling.

138 r receptor 1 (FGFR1)-5-hydroxytryptamine 1A (5-HT1A) receptor complexes have been demonstrated and th

139 promoter, so that they are only expressed in 5-HT1A receptor-containing cells.

140 esults demonstrate that drugs that stimulate 5-HT1A receptors counteract respiratory abnormalities in

141 5-HT1A receptors couple to many signaling pathways in CH

142 )p, 10[-5] M) to determine the percentage of 5-HT1A receptors coupled to G proteins.

143 have studied the effect of PKC activation on 5-HT1A receptor coupling of Ca2+ currents and 5-HT-induc

144 daptive mechanisms that occur in response to 5-HT1A receptor deletion are insufficient to oppose incr

145 compromises the accuracy of measurements of 5-HT1A receptor densities in adjacent areas of brain bec

146 5-HT1A receptor densities ranged from 7 to 63 fmol/mg ti

147 ts applicability to measuring brain regional 5-HT1A receptor densities.

148 esearch with PET for measuring serotonin 1A (5-HT1A) receptor densities in brain regions of human sub

149 s, frontal cortex and amygdala, EEDQ reduced 5-HT1A receptor density (33-70%) and drug affinity (2.3-

150 ted behaviors and suggest that reductions in 5-HT1A receptor density due to genetic defects or enviro

151 ases in social behaviors are 5-HT2A, but not 5-HT1A, receptor dependent.

152 We determined that stimulation of the 5-HT1A receptor did not contribute to this improvement i

153 ent report, we demonstrate that mice without 5-HT1A receptors display decreased exploratory activity

154 ) F-Mefway therefore may be used to quantify 5-HT1A receptor distribution in brain regions for the st

155 and quantification for static measurement of 5-HT1A receptor distribution.

156 titive control of Gi/o pathway activation in 5-HT1A receptor domains in the dorsal raphe nucleus (DRN

157 ic alpha1 and alpha2 receptors; serotonergic 5-HT1A receptors; dopaminergic D1/5 receptors by using q

158 articular interest is the serotonin type-1A (5-HT1A) receptor, due to its putative role in mediating

159 We demonstrate here that the human 5-HT1A receptor expressed in Chinese hamster ovary cells

160 revealed that these developmental changes in 5-HT1A receptor expression occurred coincident with a po

161 The highest levels of 5-HT1A receptor expression were found in neonatal HMs, w

162 findings strengthen prior speculations that 5-HT1A receptor function is modulated by estrogen.

163 indicate that the targeted disruption of the 5-HT1A receptor gene leads to heritable perturbations in

164 Altered regulation of the serotonin-1A (5-HT1A) receptor gene is implicated in major depression

165 activities at both the 5-HT transporter and 5-HT1A receptor, good selectivity over the alpha1-adrene

166 results reveal the broad dependence that the 5-HT1A receptor has on plasma membrane properties, demon

167 5-HT1A receptors in line with evidence that 5-HT1A receptors have a role in mediating emotional proc

168 Serotonin 5-HT1A receptors have been implicated in disorders of th

169 Current PET radioligands targeting 5-HT1A receptors have limitations hindering widespread P

170 -HT1A autoreceptors by being part of a FGFR1-5-HT1A receptor heterocomplex in the midbrain raphe 5-HT

171 e cells, evidence for the existence of FGFR1-5-HT1A receptor heterocomplexes in the dorsal and median

172 upled serotonin (5-hydroxytryptamine (5-HT)) 5-HT1A receptor, heterologously expressed in Chinese ham

173 (18) F-Mefway appears to be an effective 5-HT1A receptor imaging agent in all models, including h

174 uptake and, in turn, its spillover on brain 5-HT1A receptor imaging were assessed by PET with venous

175 gh the authors observed a greater density of 5-HT1A receptor immunoreactivity in H-Agg hamsters withi

176 The abundance of 5-HT1A receptor immunoreactivity on nerves of the gut an

177 2A), serotonin 2C (5-HT2C) and serotonin 1A (5-HT1A) receptors, implicated in the development of anxi

178 Translation of imaging the 5-HT1A receptor in animal models to humans will facilita

179 binding of [11C--carbonyl] WAY100635 to the 5-HT1A receptor in men, but not women.

180 We have inactivated the gene encoding the 5-HT1A receptor in mice and found that receptor-deficien

181 adiotracer for PET experiments examining the 5-HT1A receptor in neuropsychiatric disorders and drug i

182 Based on the role of the 5-HT1A receptor in the feedback regulation of the 5-HT s

183 tural immunocytochemical localization of the 5-HT1A receptor in the parabrachial (VTApb) and paranigr

184 rements show simultaneous trafficking of the 5-HT1A receptor in two distinct endosomal recycling path

185 ter the density or the degree of coupling of 5-HT1A receptors in any brain regions.

186 graphic analyses of [3H]8-OH-DPAT binding to 5-HT1A receptors in brains of these rats were conducted.

187 We therefore knocked down 5-HT1A receptors in either the dorsal raphe (presynaptic

188 ns of decreased immunoreactive perikarya and 5-HT1A receptors in fluoxetine-treated hamsters.

189 Knockdown of 5-HT1A receptors in hippocampus, but not dorsal raphe, s

190 innervation of nXII and in the expression of 5-HT1A receptors in HMs during the early postnatal perio

191 ine on the density and G protein coupling of 5-HT1A receptors in hypothalamic nuclei and other brain

192 rsive stimuli and that this is linked to DRN 5-HT1A receptors in line with evidence that 5-HT1A recep

193 of DA D2 receptors in mPFC or activation of 5-HT1A receptors in OFC increases impulsive choice in th

194 on terminals and glia, suggesting a role for 5-HT1A receptors in presynaptic and glial functions, as

195 ial of 18F-FCWAY to act as a radioligand for 5-HT1A receptors in rat brain and also revealed extensiv

196 FCWAY, results in effective imaging of brain 5-HT1A receptors in rat.

197 e as an effective platform for investigating 5-HT1A receptors in rodent models of neuropsychiatric co

198 e influence of pharmacological activation of 5-HT1A receptors in specific brain regions, this neuroim

199 ted offensive aggression by an activation of 5-HT1A receptors in the AH.

200 that the agonist activation of post-synaptic 5-HT1A receptors in the basolateral nucleus of the amygd

201 Finally, we demonstrate that activation of 5-HT1A receptors in the dBNST is necessary for the anxio

202 r the results suggest that the activation of 5-HT1A receptors in the DRN results from the local relea

203 hat serotonin signaling through postsynaptic 5-HT1A receptors in the hippocampus is critical for the

204 nd Ad-1AP-antisense) were used to manipulate 5-HT1A receptors in the hypothalamus.

205 The density and the function of 5-HT1A receptors in the medial hypothalamus were signifi

206 hypothalamus of SERT knock-out mice restored 5-HT1A receptors in the medial hypothalamus; this effect

207 support earlier findings that activation of 5-HT1A receptors in the mediobasal hypothalamus inhibits

208 itory effects of substance P, implicating DR 5-HT1A receptors in this response.

209 played unexpectedly low selective binding to 5-HT1A receptors in vivo.

210 f research have implicated the serotonin 1A (5-HT1A) receptor in major depressive disorder (MDD).

211 ed decreased density of 5-hydroxytryptamine (5-HT1A) receptors in the hypothalamus, amygdala, and dor

212 or the serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor in recombinant cells expressing human

213 etine persistently upregulated SERT, but not 5-HT1A receptors, in both the neocortex and the hippocam

214 Evidence that 5-HT1A receptor inactivation increases the therapeutic e

215 Here, activated 5-HT1A receptors inhibit firing and, thereby, muscle con

216 the serotonergic (5-HT) system, of which the 5-HT1A receptor is an essential component.

217 rastructural level, to determine whether the 5-HT1a receptor is important for the maintenance of syna

218 Hypo-responsiveness of the 5-HT1A receptor is linked to anxiety and constitutive de

219 tine-induced desensitization of hypothalamic 5-HT1A receptors is not mediated by changes in receptor

220 further demonstrate that tonic activation of 5-HT1A receptors is not responsible for the absence of s

221 has been characterized as an agonist at the 5-HT1A receptor, it also acts at other receptor sites in

222 l raphe neurons (DRN), of wild-type (WT) and 5-HT1A receptor knock out (KO) mice.

223 Motor maps derived in 5-HT1A receptor knock-out mice also showed higher moveme

224 d chronic stimulant effects of cocaine using 5-HT1A receptor ligands in autoreceptor preferring doses

225 5-HT1A receptor ligands were ineffective.

226 on-specific and age-dependent alterations in 5-HT1A receptors may be of pathophysiological significan

227 These results suggest that stimulation of 5-HT1A receptors may inhibit amphetamine-induced release

228 s favorable in vivo properties for serotonin 5-HT1A receptor measurements in humans.

229 This process is underpinned by 5-HT1A receptor-mediated activation of G-protein-coupled

230 nhibitors during development, have amplified 5-HT1A receptor-mediated currents in adulthood.

231 athrin-mediated endocytosis was required for 5-HT1A receptor-mediated Erk1/2 activation, we postulate

232 nsitive phosphodiesterase had no effect upon 5-HT1A receptor-mediated Erk1/2 activation.

233 ted depolarization and the appearance of the 5-HT1A receptor-mediated hyperpolarization appears to re

234 hesis in mouse DRN brain slices by recording 5-HT1A receptor-mediated inhibitory postsynaptic current

235 n slices evoked serotonin release produced a 5-HT1A receptor-mediated inhibitory postsynaptic current

236 These data demonstrate that the 5-HT1A receptor mediates MAPK activity by convergence up

237 We also found divergent 5-HT1A receptor mRNA expression within some of these sam

238 effect of maternal deprivation on 5-HT2A and 5-HT1A receptor mRNA levels in the developing brain.

239 eroid receptor agonists on the expression of 5-HT1A receptor mRNA were measured in rat hippocampal cu

240 e used gene-targeting technology to generate 5-HT1A receptor-mutant mice.

241 The 5-HT1A receptors not only preferentially caused voltage-

242 5-HT1A receptor-null mutant mice have potential as a mod

243 These data suggest that differences in 5-HT1A receptor number may contribute to the exaggerated

244 The affinities for 5-HT1A receptors of other cyclized amide derivatives, 5-

245 In order to investigate the role of the 5-HT1A receptors of the amygdala in modulating anxiety,

246 ty, we investigated the impact of activating 5-HT1A receptors on post-C5 SCI respiratory dysfunction.

247 cAMP sufficient to uncover previously silent 5-HT1A receptors on presynaptic nerve terminals within t

248 e sexual behavior through stimulation of the 5-HT1A receptor or the dopamine D2 receptor.

249 As serotonin 1A (5-HT1A) receptors participate in the inhibition of aggre

250 Brain serotonin 1A (5-HT1A) receptors play an important role in mood disorde

251 s demonstrate that serotonin, acting through 5-HT1A receptors, plays an excitatory role in forelimb m

252 ntributions of various pre- and postsynaptic 5-HT1A receptor populations to the behavioral effects of

253 Availability of DRN 5-HT1A receptors positively correlated with amygdala con

254 to anxiety and constitutive deletion of the 5-HT1A receptor produces anxiety-like behaviors in the m

255 Co-expression of the 5-hydroxytryptamine1A (5-HT1A) receptor promoted binding of [35S]GTPgammaS to a

256 y, in part, be mediated by activation of the 5-HT1A receptor protomer in the hippocampal FGFR1-5-HT1A

257 M-dependent activation of Erk1/2 through the 5-HT1A receptor reflects its role in endocytosis of the

258 results demonstrate that medial hypothalamic 5-HT1A receptors regulate stress responses and locomotor

259 t estrogen modulates the function of central 5-HT1A receptors regulating heart rate.

260 ey were blocked by antagonists of 5-HT2A and 5-HT1A receptors, respectively.

261 Herein, the potentiation of the 5-HT1A receptor response is disclosed, and a study of th

262 ther than potentiate the 5-HT2A, but not the 5-HT1A, receptor response, further suggesting that such

263 mediated, at least partially, by changes in 5-HT1A receptor sensitivity.

264 eta2AR) and serotonin 5-hydroxytryptamine1A (5-HT1A) receptor sequence into the second intracellular

265 the promoter regions of the human and mouse 5-HT1a receptor, serotonin transporter, tryptophan hydro

266 atment significantly decreased the number of 5-HT1A receptor sites (Bmax = 108 +/- 8.20 fmol/mg prote

267 Pretreatment with the 5-HT1A receptor-specific antagonist N-[2-[4-(2-methoxyph

268 nts of beta-arrestin1 and dynamin attenuated 5-HT1A receptor-stimulated Erk1/2 activation.

269 ncreases basal cortical dopamine release via 5-HT1A receptor stimulation, and inhibits clozapine-indu

270 l gamma oscillations in both species via the 5-HT1A receptor subtype.

271 red target site by DPAT and buspirone is the 5-HT1A receptor, than the same 5-HT receptor sub-type at

272 se findings suggest a reserve of cytoplasmic 5-HT1A receptors that are mobilized to functional postsy

273 pathway--as during motor exercise--activated 5-HT1A receptors that decreased motoneuronal excitabilit

274 Here, we define a mechanism downstream of 5-HT1A receptors that mediates antidepressant-like behav

275 pression-related research has focused on the 5-HT1A receptor, the 5-HT1B receptor has a lesser known

276 fector activity, confirm the coupling of the 5-HT1A receptor to Gz and extend the list of receptors t

277 To evaluate the contribution of serotonin 5-HT1A receptors to the regulation of these processes, w

278 To evaluate the contribution of hypothalamic 5-HT1A receptors to these phenotypes of SERT knock-out m

279 as an inhibitory effect on one branch of the 5-HT1A receptor transduction fork, namely inhibition of

280 d protein kinase, by human G protein-coupled 5-HT1A receptor transfected into CHO-K1 cells in a stabl

281 he dBNST modulates anxiety-like behavior via 5-HT1A receptors under naturalistic conditions.

282 milarly, the degree of G protein coupling to 5-HT1A receptors varied markedly among hypothalamic nucl

283 mRNA encoding 5-HT1A receptors was found in the majority of neurons in

284 -DPAT to serotonin7 (5-HT7) and serotonin1A (5-HT1A) receptors was investigated by competitive inhibi

285 In addition, while the effects of the 5-HT1A receptor were limited, the broad effects of 5-HT3

286 oquinoline (EEDQ) to irreversibly inactivate 5-HT1A receptors were investigated in female Fischer 344

287 5-HT1A receptors were labeled by 2 nM [3H]8-hydroxy-2-(d

288 Serotonin-5-HT1A receptors were measured with [3H]8-hydroxy-2-(di-

289 No significant age-related changes in 5-HT1A receptors were observed in any regions examined.

290 31) (Kd = 0.36 nM), as potential ligands for 5-HT1A receptors were reported previously.

291 3, having potent affinity for both DA D2 and 5-HT1A receptors, were evaluated for intrinsic activity

292 ght carbon atoms impart reduced affinity for 5-HT1A receptors whereas groups longer than nine carbon

293 omography (PET) imaging studies of serotonin 5-HT1A receptors which are implicated in various brain f

294 ferent aspects of the depolarization, and of 5-HT1A receptors, which signal the late developing hyper

295 inds selectively to the 5-hydroxytryptamine (5-HT1A) receptor, which is expressed on pyramidal neuron

296 nergic modulation of 5-hydroxytryptamine 1A (5-HT1A) receptors, which hyperpolarizes the activation r

297 e electrophysiological effects of prefrontal 5-HT1A receptors with implications for neuropsychiatric

298 iodinated antagonists for in vivo imaging of 5-HT1A receptors with SPECT, a series of new arylpiperaz

299 e of the compounds had high affinity for the 5-HT1A receptor, with the 5-methoxy substitution being m

300 Interactions between NK1 and 5-HT1A receptors within DR neural networks may contribut